Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC).

Fury MG, Sherman E, Ho A, Katabi N, Sima C, Kelly KW, Nwankwo O, Haque S, Pfister DG.

Cancer Chemother Pharmacol. 2012 Jul;70(1):121-8. doi: 10.1007/s00280-012-1894-y. Epub 2012 May 27.

PMID:
22644799
2.

Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Shin DM, Khuri FR, Glisson BS, Ginsberg L, Papadimitrakopoulou VM, Clayman G, Lee JJ, Ang KK, Lippman SM, Hong WK.

Cancer. 2001 Apr 1;91(7):1316-23.

PMID:
11283932
3.

Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma.

Clark JI, Hofmeister C, Choudhury A, Matz G, Collins S, Bastian R, Melian E, Emami B, Petruzzelli G.

Cancer. 2001 Nov 1;92(9):2334-40.

PMID:
11745288
4.

Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.

Saba NF, Hurwitz SJ, Magliocca K, Kim S, Owonikoko TK, Harvey D, Ramalingam SS, Chen Z, Rogerio J, Mendel J, Kono SA, Lewis C, Chen AY, Higgins K, El-Deiry M, Wadsworth T, Beitler JJ, Shin DM, Sun SY, Khuri FR.

Cancer. 2014 Dec 15;120(24):3940-51. doi: 10.1002/cncr.28965. Epub 2014 Aug 7.

5.

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179).

Kollmannsberger C, Hirte H, Siu LL, Mazurka J, Chi K, Elit L, Walsh W, Sederias J, Doyle A, Eisenhauer EA, Oza AM.

Ann Oncol. 2012 Jan;23(1):238-44. doi: 10.1093/annonc/mdr063. Epub 2011 Mar 29.

6.

Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.).

Galetta D, Giotta F, Rosati G, Gebbia V, Manzione L, Di Bisceglie M, Borsellino N, Colucci G.

Anticancer Res. 2005 Nov-Dec;25(6C):4445-9.

8.
9.

Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neck.

Pivot X, Cals L, Cupissol D, Guardiola E, Tchiknavorian X, Guerrier P, Merad L, Wendling JL, Barnouin L, Savary J, Thyss A, Schneider M.

Oncology. 2001;60(1):66-71.

PMID:
11150911
10.

Paclitaxel and carboplatin in recurrent or metastatic head and neck cancer: a phase II study.

Fountzilas G, Athanassiadis A, Samantas E, Skarlos D, Kalogera-Fountzila A, Nikolaou A, Bacoyiannis H, Stathopoulos G, Kosmidis P, Daniilidis J.

Semin Oncol. 1997 Feb;24(1 Suppl 2):S2-65-S2-67.

PMID:
9045340
11.

Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.

Rao GG, Rogers P, Drake RD, Nguyen P, Coleman RL.

Gynecol Oncol. 2005 Jan;96(1):168-72.

PMID:
15589596
12.

Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.

Briasoulis E, Golfinopoulos V, Karina M, Papakostas P, Pavlidis N, Fountzilas G.

Anticancer Drugs. 2010 Sep;21(8):785-9. doi: 10.1097/CAD.0b013e32833d5ec0.

PMID:
20647930
13.

Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.

Shin DM, Glisson BS, Khuri FR, Lippman SM, Ginsberg L, Diaz E Jr, Papadimitrakopoulou V, Feng L, Francisco M, Garden A, Kies MS, Myers J, Clayman G, Hong WK.

Cancer. 2002 Jul 15;95(2):322-30.

14.

The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck.

Suntharalingam M, Haas ML, Conley BA, Egorin MJ, Levy S, Sivasailam S, Herman JM, Jacobs MC, Gray WC, Ord RA, Aisner JA, Van Echo DA.

Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):49-56.

PMID:
10758304
15.
16.

A phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma.

Dunphy FR, Boyd JH, Kim HJ, Dunphy CH, Harrison BR, Dunleavy TL, Rodriguez JJ, McDonough EM, Minster JR, Hilton JG.

Cancer. 1997 May 15;79(10):2016-23.

PMID:
9149030
17.

A phase II study of carboplatin and paclitaxel for recurrent or metastatic head and neck cancer.

Ferrari D, Fiore J, CodecĂ  C, Di Maria G, Bozzoni S, Bordin V, Caldiera S, Luciani A, Zonato S, Floriani I, Foa P.

Anticancer Drugs. 2009 Mar;20(3):185-90. doi: 10.1097/CAD.0b013e328325a9d7.

PMID:
19396017
18.

Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.

Hainsworth JD, Gray JR, Stroup SL, Kalman LA, Patten JE, Hopkins LG, Thomas M, Greco FA.

J Clin Oncol. 1997 Dec;15(12):3464-70.

PMID:
9396399
19.

Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.

Hussain M, Gadgeel S, Kucuk O, Du W, Salwen W, Ensley J.

Cancer. 1999 Dec 1;86(11):2364-9.

PMID:
10590379
20.

Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study conducted by the Hellenic Cooperative Oncology Group.

Fountzilas G, Skarlos D, Athanassiades A, Kalogera-Fountzila A, Samantas E, Bacoyiannis C, Nicolaou A, Dombros N, Briasoulis E, Dinopoulou M, Stathopoulos G, Pavlidis N, Kosmidis P, Daniilidis J.

Ann Oncol. 1997 May;8(5):451-5.

Items per page

Supplemental Content

Write to the Help Desk